MBX Biosciences, Inc. (MBX) stock
Close on Nov 11, 2026Market cap $2.78BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.78B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.88
- Dividend yield
- –
- Free cash flow yield
- -3.57%
Fundamentals
- Net income
- -$145.12M
- EPS, diluted
- -$3.06
- Free cash flow
- -$99.33M
- Book value per share
- $9.74
- Diluted shares
- 49M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $56.33
- Open
- $56.33
- Day's range
- $55.25 – $58.56
- Volume
- 556,665
- Average volume (20 days)
- 549,761
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Nov 2024)
- Beta (5 years)
- 1.96
- 52-week range
- $23.07 – $72.64
- RSI (14 days)
- 57.4
- Volatility (1 year)
- 77.0%
- Relative volume
- 0.98×
- WACC
- 14.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MBX | S&P 500 | Difference | MBX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.4% | -2.4% | +10.8 pts | ||
| 3 months | -12.6% | -1.2% | −11.4 pts | ||
| Year to date | +83.0% | +12.3% | +70.7 pts | ||
| 1 year | +131.7% | +12.4% | +119.3 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MBX Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About MBX Biosciences
Pharmaceutical Preparations
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes precision peptide therapies to treat endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide platform to engineer drug candidates with extended action profiles and less frequent administration. Its pipeline includes canvuparatide, a parathyroid hormone peptide prodrug for chronic hypoparathyroidism; MBX 4291, a GLP-1 and GIP receptor co-agonist prodrug evaluated for obesity; and imapextide, a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia. These investigational therapies serve patients suffering from hormonal deficiencies and metabolic conditions.
Company profile, executives and historyMBX Biosciences stock: common questions
What is MBX Biosciences's stock price?
MBX closed at $57.72 on Nov 11, 2026, up 2.47% on the day. Over the past 52 weeks it traded between $23.07 and $72.64.
What is MBX Biosciences's market cap?
MBX Biosciences was worth $2.78B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MBX's P/E ratio?
MBX Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.06), so it has no meaningful P/E ratio.
Does MBX Biosciences pay a dividend?
No. MBX Biosciences has not paid a cash dividend over the last twelve months.
When does MBX Biosciences report earnings next?
MBX Biosciences is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MBX stock performed over the past year?
Including dividends, MBX returned +131.7% over the past year, against +12.4% for the S&P 500.
How many MBX shares are sold short?
4M shares were sold short at the latest FINRA report, 20.82% of the float, or 7.9 days of average trading volume.
Who are MBX Biosciences's competitors?
Companies most similar to MBX Biosciences by business, industry and size include BMEA, AMLX, VKTX, SEPN, VTVT.
See a number that looks wrong?